|Selection of source and study populations|
|Inclusion/exclusion criteria||n (%)|
|GHP members aged ≥18 years who received myelosuppressive chemotherapy from 01/01/04 - 4/30/10||3823 (100.0)|
|plus continuous health benefits during 60-day pretreatment period||3660 (95.7)|
|plus ≥2 claims with primary cancer diagnosis beginning 60 days prior to chemotherapy initiation||3193 (83.5)|
|plus admission to acute care, short stay hospital during chemotherapy course||772 (20.2)|
|plus admitted to hospital within GHS||373 (9.8)|
|plus ANC data available within 1 day of hospital admission||357 (9.3)|
GHP: Geisinger Health Plan; GHS: Geisinger Health System; ANC: absolute neutrophil count.
Weycker et al.
Weycker et al. BMC Health Services Research 2013 13:60 doi:10.1186/1472-6963-13-60